Jounce Announces Presentation At Society For Immunotherapy Of Cancer’s 30th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jounce Therapeutics, Inc., an immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients, today announced that Michael Briskin, Ph.D., vice president of research, will present an overview of Jounce’s lead Inducible T cell CO-Stimulator (ICOS) program at the Society for Immunotherapy of Cancer’s 30th Annual Meeting. Dr. Briskin will discuss insights into how the company’s translational science platform aims to prioritize indications and implement patient selection in its clinical trials.

Help employers find you! Check out all the jobs and post your resume.